Literature DB >> 25514916

Non alcoholic fatty liver: epidemiology and natural history.

Mario Masarone, Alessandro Federico, Ludovico Abenavoli, Carmela Loguercio, Marcello Persico1.   

Abstract

Non Alcoholic Fatty Liver Disease (NAFLD), defined as the presence of a significant amount of lipid accumulation in the liver (at least in 5% of hepatocytes), represents a challenging issue for the Hepatologists. NAFLD is not represented by a single entity, but rather by two different entities that have different natural history and evolution that range from simple fat accumulation in the liver (without any consequence), to necroinflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The reason of these differences has to be found in the host characteristics and associated risk factors. Globally, its prevalence among liver diseases, and in the general population, is rising in the recent years along with its associated conditions: obesity, insulin resistance, metabolic syndrome and diabetes. This increment, together with the reported clinical conditions, may be accounted for changes in dietary habits and the increase of sedentary lifestyle. Its diffusion seems to be pandemic, given that it is beginning to affect the populations in the developing world due to the spread of Western lifestyle. This is particularly worrying in young adults and children in what seems to have become the main cause of liver disease. Even if the real rate of global incidence of NAFLD are not known, its worldwide prevalence in general population is estimated to be 20-30% in Western Countries and 5-18% in Asia and it is increasing over time. In this review we will report on the global and regional prevalence of NAFLD, the principal risk factors and the natural history of its different presentations.

Entities:  

Mesh:

Year:  2014        PMID: 25514916     DOI: 10.2174/1574887109666141216111143

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  90 in total

1.  Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy.

Authors:  Jie Yan; Yang Yu; Jeon Woong Kang; Zhi Yang Tam; Shuoyu Xu; Eliza Li Shan Fong; Surya Pratap Singh; Ziwei Song; Lisa Tucker-Kellogg; Peter T C So; Hanry Yu
Journal:  J Biophotonics       Date:  2017-06-21       Impact factor: 3.207

2.  Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.

Authors:  Jie Xing; Xue Guan; Qian Zhang; Shuohua Chen; Shouling Wu; Xiujing Sun
Journal:  Obes Facts       Date:  2021-03-29       Impact factor: 3.942

3.  A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326.

Authors:  Andriana C Kaliora; Ioanna Panagiota Kalafati; Aristea Gioxari; Anastasia Diolintzi; Alexandros Kokkinos; George V Dedoussis
Journal:  Eur J Nutr       Date:  2017-07-10       Impact factor: 5.614

4.  Is possible to detect nonalcoholic fatty liver disease by a new index including single nucleotide polymorphisms (SNPs)?

Authors:  Ludovico Abenavoli; Luigi Boccuto
Journal:  Ann Transl Med       Date:  2018-09

5.  Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats.

Authors:  Xiang Qiu; Dan-Hong Gao; Xiao Xiang; Yu-Fang Xiong; Teng-Shi Zhu; Lie-Gang Liu; Xiu-Fa Sun; Li-Ping Hao
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

6.  Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuya Fukuda; Akihiro Ohbora; Takao Kojima; Michiaki Fukui
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

7.  Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit.

Authors:  Pao-Yuan Lin; Chih-Hung Chen; Christopher Glenn Wallace; Kuan-Hung Chen; Chia-Lo Chang; Hong-Hwa Chen; Pei-Hsun Sung; Kun-Chen Lin; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsueh-Wen Chang; Pei-Lin Shao; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 8.  Role of cAMP and phosphodiesterase signaling in liver health and disease.

Authors:  Banrida Wahlang; Craig McClain; Shirish Barve; Leila Gobejishvili
Journal:  Cell Signal       Date:  2018-06-11       Impact factor: 4.315

Review 9.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review.

Authors:  Pegah Golabi; Cameron T Locklear; Patrick Austin; Sophie Afdhal; Melinda Byrns; Lynn Gerber; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.